Sana Biotechnology Announces Board and Executive Changes
Ticker: SANA · Form: 8-K · Filed: 2025-09-05T00:00:00.000Z
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: SANA
TL;DR
Sana Bio (SANA) shakes up its board and exec comp. Watch for new strategy.
AI Summary
Sana Biotechnology, Inc. announced on September 4, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel. This report is filed under Item 5.02 of the 8-K form.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Sana Biotechnology, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 001-39941 (company_id) — SEC File Number
- Seattle, Washington (location) — Principal executive offices
- September 4, 2025 (date) — Date of earliest event reported
FAQ
What specific roles have seen departures or appointments?
The filing indicates the departure of certain officers and the election of directors, but does not specify the exact roles affected in this excerpt.
What are the key changes in compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not provided in this excerpt.
What is the primary reason for this 8-K filing?
The primary reason for this 8-K filing is to report the departure of directors or certain officers, the election of directors, and changes in compensatory arrangements of certain officers, as well as other events.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 4, 2025.
What is Sana Biotechnology, Inc.'s principal executive office address?
Sana Biotechnology, Inc.'s principal executive office is located at 188 East Blaine Street, Suite 400, Seattle, Washington 98102.
Filing Stats: 730 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2025-09-05 06:00:36
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq
Filing Documents
- sana-20250904.htm (8-K) — 50KB
- 0001193125-25-196414.txt ( ) — 165KB
- sana-20250904.xsd (EX-101.SCH) — 31KB
- sana-20250904_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. In connection with Mr. Cassidy's retirement described under Item 5.02 of this Current Report, the Company has entered into an offer letter with Aaron M. Grossman pursuant to which Mr. Grossman is expected to commence employment, effective as of October 20, 2025, as the Company's Executive Vice President, Chief Legal Officer. Cautionary Note Regarding Forward-Looking Statements This Current Report contains forward-looking statements regarding Mr. Cassidy's retirement and the commencement of Mr. Grossman's employment as his successor. These forward-looking statements reflect the Company's current expectations and are based on currently available information. These forward-looking statements are not guarantees and are subject to risks, uncertainties, and assumptions that are difficult to predict, including with respect to the timing and effectiveness of the events contemplated in these forward-looking statements and certain other risks covered in the Risk Factors identified in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. However, readers should carefully review the reports and documents the Company files or furnishes from time to time with the SEC, particularly its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sana Biotechnology, Inc. Date: September 5, 2025 By: /s/ Steven D. Harr, M.D. Steven D. Harr, M.D. President and Chief Executive Officer 2